TP53RK binding protein pseudogene 1Genealiases: []
Q-omics provides the consensus-scored TPRKBP1 profile across patient tissues and cancer cell-line models. TPRKBP1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TPRKBP1 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, TPRKBP1 RNA expression shows 6,065 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, LUSC, and STAD as cancer lineages where TPRKBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPRKBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPRKBP1 survival associations across molecular data types. TPRKBP1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPRKBP1 RNA expression–survival associations across cancer types. High TPRKBP1 expression shows unfavorable associations in SKCM, KIRC, PAAD and MESO, but favorable associations in OV and ESCA. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify SKCM as the clearest survival context for TPRKBP1 RNA expression.
This table summarizes TPRKBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TPRKBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPRKBP1 shows higher tumor expression in LUSC and LIHC. The LUSC box plot shows higher TPRKBP1 RNA expression in tumor versus normal tissue (log2 FC = +0.032, t-test p = .015).
This table shows molecular features associated with TPRKBP1 in patient tissues and cancer cell lines. In patient samples, TPRKBP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
